Alcentra Capital Corp (NASDAQ:ABDC) insider Branko Krmpotic bought 10,000 shares of Alcentra Capital stock in a transaction dated Tuesday, March 20th. The shares were acquired at an average cost of $6.15 per share, with a total value of $61,500.00. Following the completion of the purchase, the insider now owns 14,000 shares in the company, valued at $86,100. The acquisition was disclosed in a filing with the SEC, which is available through this link.

Shares of Alcentra Capital Corp (NASDAQ:ABDC) opened at $6.93 on Friday. Alcentra Capital Corp has a 12-month low of $5.93 and a 12-month high of $14.73. The company has a market capitalization of $95.75, a P/E ratio of 5.11 and a beta of 0.55.

How to Become a New Pot Stock Millionaire

The company also recently declared a quarterly dividend, which will be paid on Wednesday, April 4th. Investors of record on Friday, March 30th will be given a dividend of $0.18 per share. This represents a $0.72 annualized dividend and a dividend yield of 10.39%. The ex-dividend date is Wednesday, March 28th. Alcentra Capital’s payout ratio is -74.07%.

Several institutional investors and hedge funds have recently modified their holdings of ABDC. Royal Bank of Canada increased its position in shares of Alcentra Capital by 1,948.4% during the second quarter. Royal Bank of Canada now owns 8,808 shares of the asset manager’s stock worth $120,000 after purchasing an additional 8,378 shares in the last quarter. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Alcentra Capital during the third quarter worth approximately $123,000. Commerce Bank purchased a new stake in shares of Alcentra Capital during the third quarter worth approximately $159,000. Portland Investment Counsel Inc. purchased a new stake in shares of Alcentra Capital during the fourth quarter worth approximately $168,000. Finally, Goldman Sachs Group Inc. purchased a new stake in shares of Alcentra Capital during the second quarter worth approximately $219,000. Hedge funds and other institutional investors own 35.01% of the company’s stock.

Several brokerages have recently weighed in on ABDC. ValuEngine raised Alcentra Capital from a “hold” rating to a “buy” rating in a research note on Thursday. Keefe, Bruyette & Woods set a $7.00 target price on Alcentra Capital and gave the stock a “hold” rating in a research note on Thursday, March 15th. UBS raised Alcentra Capital from an “underperform” rating to a “market perform” rating in a research note on Thursday, January 11th. Finally, Raymond James Financial raised Alcentra Capital from an “underperform” rating to a “market perform” rating in a research note on Thursday, January 11th. One research analyst has rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $12.00.

WARNING: This article was first posted by Watch List News and is the property of of Watch List News. If you are viewing this article on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this article can be accessed at https://www.watchlistnews.com/insider-buying-alcentra-capital-corp-abdc-insider-buys-61500-00-in-stock/1959869.html.

About Alcentra Capital

Alcentra Capital Corporation is a specialty finance company that operates as a non-diversified, closed-end management investment company. The Company operates as a business development company and a regulated investment company. It provides customized debt and equity financing solutions to lower middle-market companies, which are companies having annual earnings, before interest, taxes, depreciation and amortization of between $5 million and $15 million, and/or revenues of between $10 million and $100 million.

Insider Buying and Selling by Quarter for Alcentra Capital (NASDAQ:ABDC)

Receive News & Ratings for Alcentra Capital Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alcentra Capital and related companies with MarketBeat.com's FREE daily email newsletter.